- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00372632
IPT of Malaria With SP in Different Zones of Drug Resistance in Rwanda
Intermittent Preventive Treatment of Malaria With Sulfadoxine-Pyrimethamine in Different Zones of Drug Resistance in Rwanda
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The present study will address the question whether the use of IPT using SP in pregnancy is efficacious in Rwanda, where it is going to be used for the first time, in areas with high levels of SP resistance. While the implementation of the new policy will take place in areas at low SP resistance level, where we expect pregnant women and newborns to benefit from it, it is of paramount importance to clarify which is the real impact of IPT/SPin areas of high SP drug resistance and at what level of SP resistance this strategy is still efficacious. As bed nets are a part of the actual control strategy of malaria in pregnancy all women will receive a bed net at enrolment.
This will be a randomized blinded placebo controlled trial: women in the 16-28th week of gestation will be offered enrolment into the study and randomized to receive IPT/SP regimen or placebo once during the second and once in the third trimesters.
The study will be conducted in Mashesha (estimated SP drug resistance 20%, 12% in 2000), Kicukiro (40% SP resistance) and Rukara (60% SP resistance). In each of these sites there are about 1000 deliveries per year. According to DHMT data, over 75% of pregnant women attend antenatal clinics, usually booking between 15 and 25 weeks of gestation. Based on this study we expect to find placental malaria prevalence over 50% in all sites.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 4
Contacten en locaties
Studie Locaties
-
-
-
Kigali, Rwanda
- Programme Nationale de Controle de Paludisms
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Pregnant women between 16-28 weeks of gestation;
- Residence within the catchment's area of the health facility;
- Willing to deliver at the health facility;
- Willing to ; adhere to all requirements of the study;
- Willing to provide written informed consent;
- Aged 21 years and above
Exclusion Criteria:
- Severe anemia (Hb < 6 g/dL)
- History of allergic reactions to sulfa drugs;
- Taking other sulfa drugs as CTX;
- History of known pregnancy complications (e.g. breech presentation, severe pre-eclampsia, prior caesarian section);
- History or presence of major illnesses likely to influence pregnancy outcome including diabetes mellitus, severe renal or heart disease, or active tuberculosis, prior to randomization;
- Any significant illness that requires hospitalization;
- Intent to move out of the study catchment's area before delivery or deliver at relative's home out of the catchment's area;
- Prior enrollment in the study or concurrent enrollment in another study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Placebo-vergelijker: placebo
|
The control group receives placebo similar in taste and appearance to to the experimental arm
|
Experimenteel: sulfadoxine-pyrimethamine
|
The intervention group receives 1500mg of sulfadoxine and 75mg of pyrimethamine at enrollment and in the third trimester.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
malaria infection will be defined as the presence of asexual stage parasites on thick smears made with maternal side placental blood and Maternal peripheral blood
Tijdsspanne: maternal placental blood at delivery; maternal peripheral blood at monthly visits between 16 weeks of gestation and delivery
|
maternal placental blood at delivery; maternal peripheral blood at monthly visits between 16 weeks of gestation and delivery
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
LBW = birth weight <2,500 grams
Tijdsspanne: at delivery
|
at delivery
|
Premature delivery = delivery prior to 37 weeks gestation
Tijdsspanne: at delivery
|
at delivery
|
Spontaneous miscarriage = any spontaneous abortion before the end of gestation
Tijdsspanne: at delivery
|
at delivery
|
Stillbirth
Tijdsspanne: at delivery
|
at delivery
|
Cord blood parasitaemia = presence of asexual stage parasites in thick smears
Tijdsspanne: at delivery
|
at delivery
|
Neonatal death = infant death within the first 28 days of life
Tijdsspanne: 7days and 6 weeks after delivery
|
7days and 6 weeks after delivery
|
Maternal anemia = Hb <11.0 g/dL
Tijdsspanne: at monthly visits between 16 weeks of gestation and delivery
|
at monthly visits between 16 weeks of gestation and delivery
|
Maternal severe anemia = Hb <6 g/dL
Tijdsspanne: at monthly visits between 16 weeks of gestation and delivery
|
at monthly visits between 16 weeks of gestation and delivery
|
Symptomatic maternal malaria infection = axillary temperature 37.5°C and asexual parasitaemia
Tijdsspanne: at monthly visits between 16 weeks of gestation and delivery
|
at monthly visits between 16 weeks of gestation and delivery
|
Severe maternal adverse reactions to SP = severe cutaneous reactions (e.g., erythema multiform, Stevens-Johnson syndrome, or toxic epidermal necrolysis)
Tijdsspanne: at monthly visits between 16 weeks of gestation and delivery plus at day 7 and week 6 after delivery
|
at monthly visits between 16 weeks of gestation and delivery plus at day 7 and week 6 after delivery
|
Medewerkers en onderzoekers
Onderzoekers
- Studie directeur: Umberto D'Alessandro, MD,MSc, PHD, Institute of Tropical Medicine Antwerp
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Infecties
- Vector overgedragen ziekten
- Parasitaire ziekten
- Protozoaire infecties
- Malaria
- Moleculaire mechanismen van farmacologische werking
- Anti-infectieuze middelen
- Enzymremmers
- Antiprotozoaire middelen
- Antiparasitaire middelen
- Antimalariamiddelen
- Foliumzuurantagonisten
- Anti-infectieuze middelen, urine
- Nier agenten
- Pyrimethamine
- Sulfadoxine
- Fanasil, combinatie van pyrimethamine-geneesmiddelen
Andere studie-ID-nummers
- 05 34 5 520
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Non HIV Infected Pregnant Women
-
Azienda Socio Sanitaria Territoriale degli Spedali...VoltooidHIV-infecties | HIV-gerelateerd lymfoomItalië
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Nog niet aan het wervenLymfoom | Lymfoom, non-Hodgkin | Non-Hodgkin-lymfoom | Non-Hodgkin lymfoom | Refractair B-cel non-Hodgkin-lymfoom | Refractair non-Hodgkin-lymfoom | Hoogwaardig B-cellymfoom | CZS lymfoom | Lymfomen Non-Hodgkin B-cel | Recidiverend non-Hodgkin-lymfoom | Lymfoom, Non-Hodgkin | Groot B-cellymfoom | Lymfoom, non-Hodgkin... en andere voorwaarden
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)IngetrokkenHIV-infectie | Recidiverend Hodgkin-lymfoom | Recidiverend non-Hodgkin-lymfoom | AIDS-gerelateerd non-Hodgkin-lymfoom | AIDS-gerelateerd Hodgkin-lymfoomVerenigde Staten
-
ANRS, Emerging Infectious DiseasesUniversity Hospital, Grenoble; Hopital Antoine Beclere; Dr Yassine Taoufik Dr Houria... en andere medewerkersVoltooid
-
City of Hope Medical CenterActief, niet wervendHIV-infectie | AIDS-gerelateerd non-Hodgkin-lymfoom | AIDS-gerelateerd plasmablastisch lymfoom | AIDS-gerelateerd primair effusielymfoomVerenigde Staten
-
National Institute of Allergy and Infectious Diseases...VoltooidHIV-infecties | Lymfoom, non-HodgkinVerenigde Staten
-
National Institute of Allergy and Infectious Diseases...Schering-PloughVoltooidHIV-infecties | Lymfoom, non-HodgkinVerenigde Staten
-
French National Agency for Research on AIDS and...BeëindigdHIV-infecties | Lymfoom, non-HodgkinFrankrijk
-
RibozyomeVoltooidHIV-infecties | Lymfoom, non-HodgkinVerenigde Staten
-
AIDS Malignancy ConsortiumCenter for International Blood and Marrow Transplant ResearchActief, niet wervendHIV-infecties | Lymfoom, folliculair | Lymfoom, B-cel | Lymfoom, grote B-cel, diffuus | Lymfoom, non-Hodgkin | Folliculair lymfoom | Leukemie | Leukemie, lymfoblastisch | HIV-geassocieerd lymfoom | HIV-ziekte; lymfoomVerenigde Staten
Klinische onderzoeken op placebo
-
SamA Pharmaceutical Co., LtdOnbekendAcute bronchitis | Acute bovenste luchtweginfectieKorea, republiek van
-
National Institute on Drug Abuse (NIDA)VoltooidCannabisgebruikVerenigde Staten
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyVoltooidMannelijke proefpersonen met diabetes type II (T2DM)Duitsland
-
Heptares Therapeutics LimitedVoltooidFarmacokinetiek | Veiligheid problemenVerenigd Koninkrijk
-
Soroka University Medical CenterVoltooid
-
Regado Biosciences, Inc.VoltooidGezonde vrijwilligerVerenigde Staten
-
Texas A&M UniversityNutraboltVoltooidGlucose and Insulin Response
-
Longeveron Inc.BeëindigdHypoplastisch linkerhartsyndroomVerenigde Staten
-
ItalfarmacoVoltooidBecker spierdystrofieNederland, Italië